Selecta Biosciences, Inc. Company Profile
Selecta Biosciences, Inc. is a biopharmaceutical company developing an entirely new class of targeted vaccines that induces an antigen-specific immune activation or antigen-specific immune tolerance for therapeutic and prophylactic applications. Selecta's proprietary Synthetic Vaccine Particle (SVPâ¢) platform creates a new paradigm in vaccine development, enabling completely new therapeutic applications while offering the potential of improved efficacy and safety profiles. Selectaâs fully synthetic engineering of novel vaccines offers a number of compelling benefits, including flexible modular vaccine design and accelerated development timelines using robust manufacturing processes. Selectaâs SVP⢠platform technology is flexible to enable diverse vaccines and the company has created targeted antigen-specific Synthetic Vaccine Particles (tSVPâ¢) and targeted antigen-specific tolerogenic Synthetic Vaccine Particles (t2SVPâ¢).
News Articles
Selecta Biosciences, Sanofi To Develop Immunotherapies For Up To 3 Allergies
PARIS (dpa-AFX) - Selecta Biosciences Inc. has reached a strategic global collaboration with Sanofi (SNY, SNYNF) to discover antigen-specific immunotherapies for life-threatening allergies. Pursua...
Sanofi, Selecta sign $900m deal to develop food allergy therapies
French drugmaker, Sanofi, enters into a collaboration with Selecta Biosciences in a deal worth up to $900m to develop food allergy therapies. Sanofi has entered into a strategic global collaboration...
Selecta secures first pharma deal as CEO decamps to Russia
Selecta Biosciences has signed an agreement with Sanofi to discover and develop antigen-specific immunotherapies for serious allergies. Selecta also reports that its president and CEO Werner Cautreel...
Selecta, Sanofi Team Up To Find Immunotherapies For Life-threatening Allergies
PARIS (dpa-AFX) - Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, Wednesday said it has entered into a strategic global collaboration with French drugmaker Sanofi (SNY, SNYN...
Sanofi, Selecta sign allergy immunotherapy deal worth up to $900M
Sanofi agreed to use Selecta Biosciences' vaccine technology to develop one immunotherapy for a life-threatening food allergy -More-
Selecta, Sanofi in food allergy deal
Selecta Biosciences Inc. (Watertown, Mass.) granted Sanofi (Euronext:SAN; NYSE:SNY) exclusive, worldwide rights to develop and commercialize a tolergenic, antigen-specific immunotherapy against an und...
Selecta wins allergy deal with Sanofi worth up to $900 mln
PARIS, Nov 28 (Reuters) - U.S. vaccine company Selecta Biosciences has signed a deal worth as much as $900 million with French drugmaker Sanofi to develop therapies for life-threatening food allergies...
Selecta Biosciences and Sanofi collaborate to develop antigen-specific immunotherapies
Selecta Biosciences has entered into a strategic global collaboration with Sanofi to discover highly targeted, antigen-specific immunotherapies for life-threatening allergies. Under the agreement, San...
Drugs and Medications
Naturally nova scotia hand sanitizer [Owen Biosciences, Inc.]
Drug Facts
Anhydrous spf 30 [Owen Biosciences, Inc.]
Drug Facts
Anhydrous spf 30 [Owen Biosciences, Inc.]
Drug Facts
Natelle one [Azur Pharma, Inc.]
Natelle OneRx Prenatal Vitamin & Plant-Based DHA Now with 28 mg Iron
Natelle one [Azur Pharma, Inc.]
Natelle®OneRx Prenatal Vitamin & Plant-Based DHA
PubMed Articles
New wrestling rules of anti-inflammatory transrepression by oxysterol receptor LXR revealed.
When life comes to an end: lessons from microbial aging models.
Introduction to Special Issue ECCS'10 in Theory in Biosciences.
Introduction to special issue ECCS'09 in Theory in Biosciences.
We previously reported that dipeptidyl peptidase IV (DPP4)-deficient rats were susceptible to dyslipidemia induced by streptozotocin (STZ). Hence, it is suggested that DPP4 is important for lipid meta...
Clinical Trials
Treatment of Alveolar Bone Defects Using Aastrom Biosciences Autologous Tissue Repair Cell Therapy
The purpose of this research is to determine if a subject's own bone marrow tissue can help regenerate bone in the area of his/her jaw where a tooth has been removed using Tissue Repair Ce...
We seek to improve the predictive accuracy of the nomogram to predict survival for patients with castrate mets disease through the addition of pathological data, the results of automated m...
Companies
Selecta Biosciences, Inc. is a biopharmaceutical company developing an entirely new class of targeted vaccines that induces an antigen-specific immune activation or antigen...
Valent BioSciences Corporation
Headquartered in Libertyville, IL, Valent BioSciences is a subsidiary of Tokyo-based Sumitomo Chemical Company and is the worldwide leader in the development, manufacturing and co...
JeNu Biosciences was founded in 2008 by a team of ultrasound scientists, medical doctors and beauty executives and is currently led by Wayne Wager, CEO. JeNu Biosciences is a Seat...
DaVinci Biosciences LLC is a privately held company dedicated to advancing therapies that improve the quality of life for individuals suffering from trauma, disease and degenerative disorders. Through...
BD Biosciences Bioimaging gives "sight" to computers, by creating software that captures images from digital cameras and extracts information from those images. We integrate our software into high-per...
More Information about "Selecta Biosciences, Inc." on BioPortfolio
We have published hundreds of Selecta Biosciences, Inc. news stories on BioPortfolio along with dozens of Selecta Biosciences, Inc. Clinical Trials and PubMed Articles about Selecta Biosciences, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Selecta Biosciences, Inc. Companies in our database. You can also find out about relevant Selecta Biosciences, Inc. Drugs and Medications on this site too.
